Please login to the form below

Not currently logged in
Email:
Password:

BI 655066

This page shows the latest BI 655066 news and features for those working in and with pharma, biotech and healthcare.

Janssen files Stelara follow-up guselkumab in Europe

Janssen files Stelara follow-up guselkumab in Europe

AZ) MEDI2070 candidate, tildrakizumab from Sun Pharma (formerly MSD) and Boehringer Ingelheim/AbbVie's BI 655066, all of which are still in clinical trials.

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Acquisition - company. $600. Boehringer Ingelheim/ AbbVie. BI-655066: anti-IL-23 MAb in Phase III for psoriasis and other autoimmune disorders; and BI-655064: anti-CD-40 MAb in Phase I.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics